Related Experiment Videos
Diabetic dyslipidemia: a case for aggressive intervention in the absence of clinical trial and cost effectiveness
1Department of Medicine, University of Toronto, Ontario.
Insights
Diabetic dyslipidemia, characterized by high triglycerides and low HDL cholesterol, significantly increases cardiovascular disease risk. While treatments exist, definitive proof of lipid-lowering therapy benefits in diabetes is still lacking.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Disorders
Background:
- Diabetes mellitus substantially elevates atherosclerotic cardiovascular disease (ASCVD) risk.
- Traditional ASCVD risk factors are present in diabetes but do not fully explain the increased risk.
- Diabetic dyslipidemia, including hypertriglyceridemia and low HDL cholesterol, is common and atherogenic.
Purpose of the Study:
- To review the evidence linking diabetic dyslipidemia to ASCVD.
- To assess the effectiveness of current treatments for diabetic dyslipidemia.
- To identify gaps in knowledge regarding lipid-lowering therapy in diabetes.
Main Methods:
- Literature review and synthesis of existing evidence.
- Analysis of lipid abnormalities in diabetes mellitus.
- Evaluation of treatment strategies for diabetic dyslipidemia.
Main Results:
- Diabetic dyslipidemia is a prevalent and proatherogenic condition.
- Conservative and pharmacological treatments can normalize lipid abnormalities.
- Few trials have specifically evaluated lipid-lowering therapy in diabetic patients, lacking definitive proof of benefit.
Conclusions:
- Despite lack of definitive proof, treating diabetic dyslipidemia is predicted to reduce ASCVD complications.
- Further well-controlled trials are needed to establish the efficacy and cost-effectiveness of lipid-lowering therapy in diabetes.
- Managing ASCVD risk factors, including dyslipidemia, is crucial for reducing healthcare expenditures in diabetic patients.
Abstract:
Patients with diabetes mellitus have a two- to fourfold increase in clinical manifestations of atherosclerotic cardiovascular disease (ASCVD). Traditional risk factors such as age, hypertension, left ventricular hypertrophy, hyperlipidemia and smoking are still operative in diabetes but do not account for the total increase in ASCVD risk associated with diabetes. The most common lipid abnormalities in noninsulin-dependent diabetes mellitus and poorly controlled insulin-dependent diabetes mellitus are hypertriglyceridemia and low high density lipoprotein cholesterol. Evidence is presented to support the hypothesis that these lipid abnormalities are atherogenic in diabetes. Treatment of diabetic dyslipidemia with conservative measures (diet, weight loss, aerobic exercise, improved glycemic control) and pharmacological management have been shown to be highly effective in normalizing the lipid abnormalities. However, few trials of lipid lowering therapy have included patients with known diabetes mellitus and, to date, there have been no well-controlled prospective trials of lipid lowering therapy in diabetes. There is therefore no definitive proof regarding the benefit of lipid lowering therapy in diabetes mellitus. There are also no data regarding the cost effectiveness of lipid lowering therapy in reducing ASCVD complications in diabetes. There are data, however, showing that complications of ASCVD in patients with diabetes account for a large percentage of total health care expenditures. The overwhelming evidence that patients with diabetes have a high rate of ASCVD, that traditional risk factors for ASCVD are operative in diabetes and that the dyslipidemia of diabetes is highly prevalent and proatherogenic, predicts that the treatment of ASVD risk factors, including dyslipidemia, will be associated with a substantial reduction in ASCVD complications.(ABSTRACT TRUNCATED AT 250 WORDS)